Giorgi J V, Majchrowicz M A, Johnson T D, Hultin P, Matud J, Detels R
Multicenter AIDS Cohort Study and University of California Los Angeles School of Medicine, 90095-1745, USA.
AIDS. 1998 Oct 1;12(14):1833-44. doi: 10.1097/00002030-199814000-00015.
To evaluate the efficacy of combination protease and reverse transcriptase inhibitor therapy in correcting HIV-1-induced lymphocyte subset abnormalities in previously treated adults.
A 48-week observational study of lymphocyte subsets in 12 participants in the Multicenter AIDS Cohort Study who were already taking at least one reverse transcriptase inhibitor and added a protease inhibitor to their treatment regimen. Comparison groups were HIV-seronegative homosexual men, HIV-seronegative heterosexual men, and homosexual HIV-1-infected men who were long-term non-progressors.
Three-color immunofluorescence and monoclonal antibodies were used to assess HIV-1-induced lymphocyte subset alterations related to immune deficiency and immune activation. Plasma HIV-1 RNA levels were monitored to assess suppression of viral replication.
CD4+ cell counts significantly increased and lymphocyte activation measured as CD38 and HLA-DR expression on CD8+ T cells significantly decreased by 48 weeks. CD4+ cell values remained abnormal even in those who were fully suppressed. Some T-cell activation markers decreased to levels observed in long-term non-progressors. The increase in CD4+ T-cell numbers reached a plateau by week 24, but the increase in resting HLA-DR- CD38-T cells was sustained through week 48. Proportions of CD45RA+ CD62L-selectin+ and CD28+ CD4+ T-cell subsets and Fas expression were not abnormal at baseline compared with seronegative homosexual controls.
The most significant impact of suppression of viral replication was reversal of T-cell activation. However, normalization of lymphocyte subset perturbations associated with chronic HIV-1 infection was not achieved after 1 year of treatment with current combination antiretroviral regimens. More profound viral suppression, therapy for longer than 1 year, or immunologic augmentation may be needed to fully reverse the abnormalities.
评估蛋白酶抑制剂与逆转录酶抑制剂联合治疗对纠正既往接受治疗的成年患者中HIV-1诱导的淋巴细胞亚群异常的疗效。
一项对多中心艾滋病队列研究中12名参与者淋巴细胞亚群进行的为期48周的观察性研究,这些参与者已在服用至少一种逆转录酶抑制剂,并在其治疗方案中添加了一种蛋白酶抑制剂。比较组为HIV血清学阴性的同性恋男性、HIV血清学阴性的异性恋男性以及长期病情无进展的HIV-1感染同性恋男性。
采用三色免疫荧光和单克隆抗体评估与免疫缺陷和免疫激活相关的HIV-1诱导的淋巴细胞亚群改变。监测血浆HIV-1 RNA水平以评估病毒复制的抑制情况。
到48周时,CD4+细胞计数显著增加,以CD8+ T细胞上CD38和HLA-DR表达衡量的淋巴细胞激活显著降低。即使在病毒完全被抑制的患者中,CD4+细胞值仍保持异常。一些T细胞激活标志物降至长期病情无进展者中观察到的水平。CD4+ T细胞数量的增加在第24周达到平台期,但静息HLA-DR-CD38-T细胞的增加持续至第48周。与血清学阴性的同性恋对照相比,CD45RA+ CD62L-选择素+和CD28+ CD4+ T细胞亚群的比例以及Fas表达在基线时并无异常。
抑制病毒复制的最显著影响是T细胞激活的逆转。然而,使用当前的联合抗逆转录病毒方案治疗1年后,与慢性HIV-1感染相关的淋巴细胞亚群紊乱并未恢复正常。可能需要更深度的病毒抑制、超过1年的治疗或免疫增强来完全逆转这些异常。